No 10Y consistency score yet for revenue — the window needs more comparable quarters.
Valuation vs own 10Y history: P/S 10.6x · 10Y median 3.4x · 89th percentile · as of Oct 6, 2026
Annualized revenue (TTM) · by quarter, last 24
Quarterly YoY revenue growth vs the 20% line
P/S multiple vs its 10Y median
FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters. Quote observation: 2026-10-06T18:37:41.365Z. Latest historical point 2026-10-05. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
Current FMP quote-based enterprise value / four-quarter operating income plus matched D&A. Quote observation: 2026-10-06T18:37:41.365Z. Latest historical point 2026-10-05. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
FMP quote market capitalization / four-quarter operating cash flow. Quote observation: 2026-10-06T18:37:41.365Z. Latest historical point 2025-08-11. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
FMP quote market capitalization / four-quarter operating cash flow less absolute capital expenditures. Quote observation: 2026-10-06T18:37:41.365Z. Latest historical point 2024-05-09. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
Unrounded diluted TTM EPS / FMP quote price × 100. Quote observation: 2026-10-06T18:37:41.365Z. Latest historical point 2024-02-29.
Four-quarter operating EBITDA / current FMP quote-based enterprise value × 100. Quote observation: 2026-10-06T18:37:41.365Z. Latest historical point 2026-10-05. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
Four-quarter operating cash flow / FMP quote market capitalization × 100. Quote observation: 2026-10-06T18:37:41.365Z. Latest historical point 2025-08-11. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
Four-quarter free cash flow / FMP quote market capitalization × 100. Quote observation: 2026-10-06T18:37:41.365Z. Latest historical point 2024-05-09. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
The latest delayed quote for Maravai LifeSciences Holdings, Inc. (MRVI) stock was $8.02 as of Oct 6, 2026, 2:35 PM EDT, down 5.87% from the previous close.
Longer view (total return, dividends reinvested): past 12 months +174.4% · 3-year avg -4.1%/yr · 5-year avg -27.6%/yr
Maravai LifeSciences Holdings, Inc. is a life sciences company operating globally, supplying essential products that facilitate the advancement of drug therapies, diagnostics, innovative vaccines, and research into human diseases.
Biotechnology · San Diego, CA
Selected amounts supplied by FMP for each displayed period. Reviewed label references appear where available; other labels are unverified, and items may overlap.
2025-12-31 · USD
Reviewed labels link to their filing; other labels are unverified FMP source labels.
Reviewed presentation labels and parent/child details link to filing evidence; other FMP source labels remain unverified. Mutual exclusivity and reconciliation to a total for the same reporting period and currency have not been verified; percentages and stacked totals are unavailable.
2025-12-31 · USD
Reviewed labels link to their filing; other labels are unverified FMP source labels.
Next Earnings Date
Nov 5, 2026
30 days away
EPS Estimate
-0.06
Revenue Est.
$43.56M
Last Quarter Results
EPS
$-0.02
vs Estimate
$-0.04
Revenue
| Stock | Market Cap | Close Price | Price Change | TTM Total Return | 5Y CAGR | 10Y CAGR | Compare |
|---|---|---|---|---|---|---|---|
| 1MRVI | $2.22B | $8.02 | -5.87% | +174.40% | -27.63% | N/A | N/A |
| 2PHVS | $2.17B | $31.07 | +1.90% | +30.19% | +11.45% | N/A | vs MRVI |
| 3HRMY | $2.29B | $39.52 | -1.00% | +46.07% | +0.91% | N/A | vs MRVI |
| 4SLS | $2.14B | $11.49 | -1.20% | +516.69% | +6.20% | -49.07% | vs MRVI |
| 5WGS | $2.14B | $71.63 | -6.08% | -35.37% | -19.67% | N/A | vs MRVI |
| 6ALMR | $2.31B | $33.27 | -12.73% | N/A | N/A | N/A | vs MRVI |
forward FY estimate
N/A
Reviewed presentation labels and parent/child details link to filing evidence; other FMP source labels remain unverified. Mutual exclusivity and reconciliation to a total for the same reporting period and currency have not been verified; percentages and stacked totals are unavailable.
$51.44M
vs Estimate
$48.67M
Consensus Rating
Based on 6 analysts
Average Price Target
$7.83
-2.3% downside
Low
$7.00
Current
$8.02
High
$9.00
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $-0.05 | $-0.05 | $-0.05 | 5 |
| Quarter ending Dec 2026 | $-0.04 | $-0.04 | $-0.03 | 4 |
| Quarter ending Mar 2027 | $-0.01 | $-0.01 | $-0.01 | 1 |
| Quarter ending Jun 2027 | $-0.03 | $-0.03 | $-0.03 | 1 |
Annual
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| FY 2026 | $-0.15 | $-0.11 | $-0.08 | 5 |
| FY 2027 | $-0.23 | $-0.10 | $-0.02 | 5 |
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $42.92M | $43.56M | $44.28M | 5 |
| Quarter ending Dec 2026 | $50.14M | $50.92M | $51.83M | 5 |
| Quarter ending Mar 2027 | $61.85M | $63.46M | $64.90M | 4 |
| Quarter ending Jun 2027 | $53.88M | $55.28M | $56.54M | 4 |
Annual
| Period |
|---|
Source: FMP Analyst Consensus Estimates. Forward P/E is unavailable for the current price and estimate observations.
| Low |
|---|
| Avg |
|---|
| High |
|---|
| # Analysts |
|---|
| FY 2026 | $210.84M | $211.77M | $213.44M | 6 |
| FY 2027 | $221.20M | $224.89M | $229.06M | 6 |
